Spots Global Cancer Trial Database for Anlotinib in Advanced Solid Tumors With FGFR Alteration
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Anlotinib in Advanced Solid Tumors With FGFR Alteration
Official Title: Anlotinib in Advanced Solid Tumors With FGFR Alteration
Study ID: NCT03929965
Conditions
Interventions
Study Description
Brief Summary: This clinical trial aims to evaluate the efficacy, safety of Anlotinib in advanced solid tumors with FGFR alteration.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Shanghai Changzheng Hospital, Shanghai, Shanghai, China
Shanghai Changzheng Hospital, Shanghai, Shanghai, China
Shanghai Changzheng Hospital, Shanghai, Shanghai, China
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
